Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen: Long COVID Awareness Month

Tevogen: Long COVID Awareness Month

WARREN, N.J., March 11, 2026 -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company’s progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month.

Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients.

Tevogen continues to prioritize the development of TVGN 489, its investigational off-the-shelf, precision T-cell therapy, to address the urgent needs of the estimated 7% of U.S. adults suffering from Long COVID.

• Clinical Foundation: Building on proof-of-concept data where 100% of treated high-risk patients did not develop Long COVID, Tevogen is finalizing the infrastructure for its next clinical phase.
• Expanded Reach: The identification of five additional HLA targets has expanded TVGN 489's potential eligibility to approximately 65% of the U.S. population, supporting the company's mission of providing accessible and equitable healthcare.
• Digital Integration: The company continues to evaluate the acquisition of Sciometrix and its Clinicus platform to enhance real-time patient monitoring and data collection during future trial.
  
  

Ryan Saadi, MD, MPH, Founder and CEO of Tevogen stated, "Long COVID is a clinical emergency affecting hundreds of millions of people globally. Our proof-of-concept data demonstrated that none of the patients treated with TVGN 489 for acute infection developed Long COVID. Our expanded HLA coverage now reaching 65% of the U.S. population, and potential digital health acquisitions move us toward building the infrastructure needed to launch our next clinical phase with precision and scale."

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements